With success in myasthenia gravis trial, Amgen's Uplizna looks set up to add new indication
Three months after Amgen revealed that Uplizna had aced a phase 3 trial in immunoglobulin G4-related disease (IgG4), the company said the anti-CD-19 antibody has excelled in a study against another neurologic disorder. In the ongoing phase 3 MINT study, …